Prostate Health Supplement by Prostacet - Health and Beauty Products

Degarelix (FIRMAGON(R)) Vs Leuprolide (Lupron Depot(R)) In Patients With Advanced Prostate Cancer: Further Analysis From A Phase III Pivotal Trial

Drs. Neal Shore and E. David Crawford presented Results for Prostate-Specific Antigen (PSA) Recurrence from the additional investigation of subordinate end points of Biochemical Recurrence chew out in a Phase III focal deliberate over of FIRMAGON® (monthly for Injection) or monthly leuprolide in Patients during the head year of Treatment. Prostate Cancer Patients who received FIRMAGON 240/80 mg/month had a Recurrence deserve of 7.7% during the word go year of care compared with 12.9% of Patients treated with leuprolide 7.5 mg/month (p=0.05). Patients being treated with FIRMAGON also had longer hour to Recurrence compared with those on leuprolide (p=0.04). Results of the PSA inquiry were presented in a broadsheet at the 10th Annual Meeting of the Society of Urologic Oncology, held in conjunction with the World Urological Oncology Federation, on December 3 in Bethesda, MD.

About the Study In the Phase III multicenter, randomized, open-label endeavour comparing degarelix with leuprolide, Prostate Cancer Patients (n=610) were randomized to a starting Dosage of degarelix 240 mg for one month, followed by monthly prolongation Doses of 80 mg (n=207) or 160 mg (n=202), or leuprolide 7.5 mg/month (n=201). Results showed that degarelix is as serviceable as leuprolide in reducing and sustaining castrate Levels of Testosterone.(1),(2) Suppression of Testosterone to castrate Levels occurred significantly faster in Patients receiving degarelix than in those receiving leuprolide.(1),(2) The chew over also showed that degarelix achieves faster crack-down of luteinizing Hormone and follicle-stimulating Hormone.(1),(2) PSA Recurrence was defined as two consecutive increases in PSA of 50% compared with nadir and greater than or peer to 5 ng/mL on two consecutive measurements at least two Weeks apart.

continue reading »

Related posts

• Prostate cancer stupefy reduces testosterone levels within 3 days (0)
• Degarelix: A New Approach For The Treatment Of Prostate Cancer (0)
• Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium (0)
• This email hail is being protected from spam bots, you destitution Javascript enabled to sight it Cancer-. (0)
• The issue must successfully complete a more far-ranging clinical trial before the U.S. (0)